Einige Inhalte dieser Anwendung sind momentan nicht verfügbar.
Wenn diese Situation weiterhin besteht, kontaktieren Sie uns bitte unterFeedback&Kontakt
1. (WO2019046233) A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS
Anmerkung: Text basiert auf automatischer optischer Zeichenerkennung (OCR). Verwenden Sie bitte aus rechtlichen Gründen die PDF-Version.

WHAT IS CLAIMED IS:

1. A method to determine a person's response to glucocorticoids comprising:

a) administering the glucocorticoid of interest to said person,

b) drawing blood from the person of step (a) 4 hours post-administration, c) isolating the RNA from the blood collected in step (b),

d) profiling the gene expression of the RNA isolated in step (c), and

e) comparing the gene signature score post-administration with a control gene signature score,

wherein an increase in the gene signature score for FKBP5, ECHDC3, IL1R2, ZBTB16, IRS2, IRAK3, ACSLl, DUSPl indicates a response to the glucocorticoid.

2. A method to determine a person's response to glucocorticoids comprising:

a) administering the glucocorticoid of interest to said person,

b) drawing blood from the person of step (a) 4 hours post-administration, c) isolating the RNA from the blood collected in step (b),

d) profiling the gene expression of the RNA isolated in step (c), and

e) comparing the gene signature score post-administration with a control gene signature score,

wherein an increase in the gene signature score for FKBP5, ECHDC3, IL1R2, ZBTB16, IRS2, IRAK3, ACSLl, DUSPl, PHC2, TLR2, TSC22D3, SLA,

CRISPLD2, MAN2A2, FAR2, CEBPD, SPTLC2, HSPA6 indicates a response to the glucocorticoid.

3. A method to determine a person's response to glucocorticoids comprising:

a) administering the glucocorticoid of interest to said person,

b) drawing blood from the person of step (a) 4 hours post-administration, c) isolating the RNA from the blood collected in step (b),

d) profiling the gene expression of the RNA isolated in step (c), and

e) comparing the gene signature score post-administration with a control gene signature score,

wherein an increase in the gene signature score for FKBP5, ECHDC3, IL1R2 indicates a response to the glucocorticoid.

4. A method to determine a person's response to glucocorticoids comprising: a) administering the glucocorticoid of interest to said person,

b) drawing blood from the person of step (a) 4 hours post-administration, c) isolating the RNA from the blood collected in step (b),

d) profiling the gene expression of the RNA isolated in step (c), and

e) comparing the gene signature score post-administration with a control gene signature score,

wherein an increase in the gene signature score for FKBP5, ECHDC3, IL1R2, ZBTB16, IRS2, IRAK3 indicates a response to the glucocorticoid.

5. A method to determine a person's response to glucocorticoids comprising:

a) administering the glucocorticoid of interest to said person,

b) drawing blood from the person of step (a) 4 hours post-administration, c) isolating the RNA from the blood collected in step (b),

d) profiling the gene expression of the RNA isolated in step (c), and

e) comparing the gene signature score post-administration with a control gene signature score,

wherein a decrease in the gene signature score for KMO, CCR5, CXCL8, FPR3, PLA2G7, PEA15, TRAFl, CSF2RB, TRDC, OLR1, KIAA0226L, FCGR2B, ATF5, CX3CR1, MYOF, SLAMF7, CD9, IL1RN indicates a response to the glucocorticoid.

6. The method of claim 1 - 5 wherein the glucocorticoid of interest is selected from the group consisting of cortisone, dexamethasone, hydrocortisone,

methylprednisolone, prednisolone, prednisone, triamcinolone, betamethasone budesonide, fluticasone, and synthetic glucocorticoids.

7. The method of claim 1 - 5 wherein the control gene signature is obtained from the same person before glucocorticoid administration or from normal healthy controls not administered the glucocorticoid.

8. The method of claim 1 - 4 wherein a 1.5-fold increase in the gene signature score compared to the control indicates a response to the glucocorticoid.

9. The method of claim 1 - 4 wherein a 2-fold increase in the gene signature score compared to the control indicates a response to the glucocorticoid.

10. A method of treating a person diagnosed with rheumatoid arthritis(RA)

comprising testing the person's response to glucocorticoids comprising:

a. administering the glucocorticoid of interest to said person,

b. drawing blood from the person of step (a) 4 hours post-administration, c. isolating the RNA from the blood collected in step (b),

d. profiling the gene expression of the RNA isolated in step (c), and e. comparing the gene signature score post-administration with a control gene signature score,

wherein an increase in the gene signature score for FKBP5, ECHDC3, IL1R2, ZBTB16, IRS2, IRAK3, ACSLl, DUSPl indicates that the person will respond to the glucocorticoid; and administering the glucocorticoid to the RA patient.

11. A method of treating a person diagnosed with systemic lupus erythematosus(SLE) comprising testing the person's response to glucocorticoids comprising:

a. administering the glucocorticoid of interest to said person,

b. drawing blood from the person of step (a) 4 hours post-administration, c. isolating the RNA from the blood collected in step (b),

d. profiling the gene expression of the RNA isolated in step (c), and e. comparing the gene signature score post-administration with a control gene signature score,

wherein an increase in the gene signature score for FKBP5, ECHDC3, IL1R2, ZBTB16, IRS2, IRAK3, ACSLl, DUSPl indicates that the person will respond to the glucocorticoid; and administering the glucocorticoid to the SLE patient.